CA2779473C - Methods of treating viral associated diseases - Google Patents

Methods of treating viral associated diseases Download PDF

Info

Publication number
CA2779473C
CA2779473C CA2779473A CA2779473A CA2779473C CA 2779473 C CA2779473 C CA 2779473C CA 2779473 A CA2779473 A CA 2779473A CA 2779473 A CA2779473 A CA 2779473A CA 2779473 C CA2779473 C CA 2779473C
Authority
CA
Canada
Prior art keywords
virus
cmx001
cells
compound
jcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2779473A
Other languages
English (en)
French (fr)
Other versions
CA2779473A1 (en
Inventor
George R. Painter
Ernest Randall Lanier
Powell Gwendolyn Painter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Biodefense Operations Lansing Inc
Original Assignee
Chimerix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chimerix Inc filed Critical Chimerix Inc
Publication of CA2779473A1 publication Critical patent/CA2779473A1/en
Application granted granted Critical
Publication of CA2779473C publication Critical patent/CA2779473C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2779473A 2009-10-30 2010-10-29 Methods of treating viral associated diseases Active CA2779473C (en)

Applications Claiming Priority (31)

Application Number Priority Date Filing Date Title
US25670109P 2009-10-30 2009-10-30
US61/256,701 2009-10-30
US32698910P 2010-04-22 2010-04-22
US32698610P 2010-04-22 2010-04-22
US32698210P 2010-04-22 2010-04-22
US32699110P 2010-04-22 2010-04-22
US61/326,986 2010-04-22
US61/326,982 2010-04-22
US61/326,989 2010-04-22
US61/326,991 2010-04-22
US32747410P 2010-04-23 2010-04-23
US61/327,474 2010-04-23
US32791410P 2010-04-26 2010-04-26
US61/327,914 2010-04-26
US32849110P 2010-04-27 2010-04-27
US61/328,491 2010-04-27
US33062410P 2010-05-03 2010-05-03
US61/330,624 2010-05-03
US33170410P 2010-05-05 2010-05-05
US61/331,704 2010-05-05
US35543010P 2010-06-16 2010-06-16
US61/355,430 2010-06-16
US40507510P 2010-10-20 2010-10-20
US40508010P 2010-10-20 2010-10-20
US40507310P 2010-10-20 2010-10-20
US40508410P 2010-10-20 2010-10-20
US61/405,075 2010-10-20
US61/405,084 2010-10-20
US61/405,073 2010-10-20
US61/405,080 2010-10-20
PCT/US2010/054779 WO2011053812A1 (en) 2009-10-30 2010-10-29 Methods of treating viral associated diseases

Publications (2)

Publication Number Publication Date
CA2779473A1 CA2779473A1 (en) 2011-05-05
CA2779473C true CA2779473C (en) 2016-08-16

Family

ID=43922582

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2779473A Active CA2779473C (en) 2009-10-30 2010-10-29 Methods of treating viral associated diseases

Country Status (6)

Country Link
US (2) US20130072458A1 (cg-RX-API-DMAC7.html)
EP (1) EP2493479A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013509433A (cg-RX-API-DMAC7.html)
AU (1) AU2010313273B2 (cg-RX-API-DMAC7.html)
CA (1) CA2779473C (cg-RX-API-DMAC7.html)
WO (1) WO2011053812A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
CN105055432A (zh) 2008-01-25 2015-11-18 奇默里克斯公司 治疗病毒感染的方法
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
CA2789443C (en) 2010-02-12 2016-09-13 Chimerix, Inc. Nucleoside phosphonate salts
EP2563367A4 (en) * 2010-04-26 2013-12-04 Chimerix Inc Methods of treating retroviral infections and related dosage regimes
CN105998039A (zh) * 2010-08-31 2016-10-12 奇默里克斯公司 膦酸酯衍生物及其合成方法
US20140303092A1 (en) * 2011-10-26 2014-10-09 Chimerix, Inc Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
CA2857490C (en) 2011-12-22 2020-03-31 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
WO2013163509A1 (en) * 2012-04-27 2013-10-31 Chimerix, Inc. A method of mitigating virus associated end-organ damage
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US9526729B2 (en) * 2013-01-29 2016-12-27 Hsiao Lily Yu Medicament for treating peripheral neuropathies
KR20150130355A (ko) 2013-03-15 2015-11-23 더 리전트 오브 더 유니버시티 오브 캘리포니아 비환식 뉴클레오사이드 포스포네이트 디에스테르
UA116825C2 (uk) 2013-11-15 2018-05-10 Чимерикс Інк. Морфологічні форми гексадецилоксипропілових складних ефірів фосфонової кислоти і способи їх синтезу
MX377983B (es) 2014-09-15 2025-03-04 Univ California Análogos de nucleótidos.
US10160778B2 (en) 2014-10-27 2018-12-25 Concert Pharmaceuticals, Inc. Pyrimidine phosphonic acid esters
EP3875462A1 (en) 2015-09-15 2021-09-08 The Regents of The University of California Nucleotide analogs
WO2017196990A1 (en) * 2016-05-12 2017-11-16 Contravir Pharmaceuticals, Inc. Methods of treating hepatitis b infections and related dosage regimes
AU2017290703B2 (en) 2016-06-28 2023-03-30 Emergent Biodefense Operations Lansing Llc Formulations of brincidofovir
WO2018156879A1 (en) * 2017-02-23 2018-08-30 Chimerix, Inc. Treatment of adenovirus with brincidofovir
WO2020138067A1 (ja) * 2018-12-25 2020-07-02 富士フイルム富山化学株式会社 ピラジン誘導体と細胞内におけるピラジン誘導体リボース三リン酸体の量を増加させる化合物とを組み合わせてなるrnaウイルス感染症治療剤
EP3946402A1 (en) * 2019-03-29 2022-02-09 Evonik Operations GmbH Preparations containing berry extracts for use in the prophylaxis and/or treatment of viral infections caused by herpesviridae
CN117285565A (zh) * 2022-06-24 2023-12-26 润佳(苏州)医药科技有限公司 核苷类似物及其医药用途
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태
JP7417339B1 (ja) 2023-08-07 2024-01-18 シンバイオ製薬株式会社 アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605602B1 (en) * 2001-09-28 2003-08-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of treating BK virus nephropathy
TW200408645A (en) * 2002-04-26 2004-06-01 Gilead Sciences Inc Non nucleoside reverse transcriptase inhibitors
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US20070292523A1 (en) * 2004-09-27 2007-12-20 Joey Moodley Dihydropyrimidine Formulations
WO2006110655A2 (en) * 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
WO2008118013A2 (en) * 2007-03-23 2008-10-02 To-Bbb Holding B.V. Targeted intracellular delivery of antiviral agents
CN101678122A (zh) * 2007-04-27 2010-03-24 奇默里克斯公司 在核苷给药的受体中降低肾中毒性的方法
WO2011017253A1 (en) * 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
US20110263536A1 (en) * 2010-04-22 2011-10-27 Chimerix, Inc. Methods of Treating Orthopox Virus Infections and Associated Diseases

Also Published As

Publication number Publication date
AU2010313273A1 (en) 2012-05-24
EP2493479A4 (en) 2013-04-17
US20130072458A1 (en) 2013-03-21
JP2013509433A (ja) 2013-03-14
AU2010313273B2 (en) 2015-04-02
CA2779473A1 (en) 2011-05-05
US20150141375A1 (en) 2015-05-21
WO2011053812A1 (en) 2011-05-05
EP2493479A1 (en) 2012-09-05

Similar Documents

Publication Publication Date Title
AU2010313273B2 (en) Methods of treating viral associated diseases
US20120164104A1 (en) Composition and Methods of Treating Viral Infections and Viral Induced Tumors
US12414961B2 (en) Substituted nucleosides and nucleotides for treating viral infections
ES2915381T3 (es) Análogos de nucleótidos
AU2024205205A1 (en) Methods for treating SARS CoV-2 infections
JP6220484B1 (ja) フィロウイルス科ウイルス感染症を処置するための方法
JP2021517132A (ja) 4’−ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用
WO2014124430A1 (en) Nucleotide and nucleoside therapeutic compositions and uses related thereto
US20140303092A1 (en) Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
WO2017106710A1 (en) Nucleotide and nucleoside therapeutic compositions and uses related thereto
US20190085013A1 (en) Nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2005511490A (ja) 抗ウイルス活性を有する6−‘2−(ホスホノメトキシ)アルコキシピリミジン誘導体
AU2015203573A1 (en) Methods of treating viral associated diseases
CN102665729A (zh) 用于治疗病毒相关性疾病的方法
EP3077403A1 (en) Branched chain acyclic nucleoside phosphonate esters and methods of synthesis and uses thereof
AU2015264949A1 (en) Composition and methods of treating viral infections and viral induced tumors
HK1240226A1 (en) Nucleotide analogs
HK1240226B (en) Nucleotide analogs

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240905

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240905

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240905

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250110

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250318

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250318

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250909

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250909

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260421

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20260421

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260806

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260806